From: Pan-cancer analysis of TCGA data reveals notable signaling pathways
Analysis | Pathway | p-value | FDR | Status | Signfct |
---|---|---|---|---|---|
pan-cancer | Focal adhesion | 5.99E-06 | 0.000789 | Activated | N |
PI3K-Akt signaling pathway | 1.01E-05 | 0.000789 | Activated | N | |
Rap1 signaling pathway | 3.71E-05 | 0.001939 | Activated | N | |
Calcium signaling pathway | 4.95E-05 | 0.001942 | Activated | N | |
Systemic lupus erythematosus | 0.001966 | 0.05302 | Activated | S | |
breast | ECM-receptor interaction | 5.71E-05 | 0.008967 | Activated | |
Complement and coagulation cascades | 0.003855 | 0.218606 | Activated | S | |
colon | Adrenergic signaling in cardiomyocytes* | 3.35E-05 | 0.001709 | Inhibited | S |
Melanoma | 3.68E-05 | 0.001709 | Inhibited | S | |
Focal adhesion | 4.73E-05 | 0.001709 | Inhibited | N | |
Cytokine-cytokine receptor interaction | 5.84E-05 | 0.001709 | Activated | S | |
Pathways in cancer* | 6.21E-05 | 0.001709 | Inhibited | S | |
PI3K-Akt signaling pathway | 6.53E-05 | 0.001709 | Inhibited | N | |
Rap1 signaling pathway | 0.002919 | 0.065477 | Inhibited | N | |
glioblastoma | Cytokine-cytokine receptor interaction | 5.12E-07 | 8.04E-05 | Inhibited | S |
Complement and coagulation cascades* | 1.33E-05 | 0.000798 | Inhibited | S | |
Systemic lupus erythematosus | 1.94E-05 | 0.000798 | Inhibited | S | |
PI3K-Akt signaling pathway | 2.31E-05 | 0.000798 | Inhibited | N | |
Chemokine signaling pathway | 2.54E-05 | 0.000798 | Inhibited | S | |
Vascular smooth muscle contraction | 0.003076 | 0.069809 | Inhibited | ||
kidney | Rap1 signaling pathway | 3.30E-06 | 0.000518 | Inhibited | N |
ECM-receptor interaction* | 8.13E-06 | 0.000638 | Inhibited | ||
Colorectal cancer* | 2.79E-05 | 0.001459 | Inhibited | ||
Focal adhesion | 8.66E-05 | 0.0034 | Inhibited | N | |
Insulin signaling pathway | 0.000557 | 0.015232 | Inhibited | ||
glioma | Focal adhesion | 4.94E-06 | 0.000674 | Inhibited | T |
ECM-receptor interaction* | 8.59E-06 | 0.000674 | Inhibited | ||
Chemokine signaling pathway | 1.74E-05 | 0.00091 | Inhibited | S | |
Small cell lung cancer* | 4.27E-05 | 0.001482 | Inhibited | S | |
Cytokine-cytokine receptor interaction | 4.72E-05 | 0.001482 | Inhibited | S | |
Retrograde endocannabinoid signaling | 0.000478 | 0.01252 | Activated | ||
Analysis | Pathway | p-value | FDR | Status | Signfct |
lung adeno. | Chemokine signaling pathway | 1.82E-08 | 2.86E-06 | Activated | S |
Cytokine-cytokine receptor interaction | 1.51E-05 | 0.001187 | Activated | S | |
Systemic lupus erythematosus | 0.000108 | 0.005654 | Activated | S | |
lung squamous | Chemokine signaling pathway | 1.43E-05 | 0.002204 | Activated | S |
Cytokine-cytokine receptor interaction | 4.14E-05 | 0.002204 | Activated | S | |
Endocrine and other factor-reg. calcium reab.* | 4.21E-05 | 0.002204 | Inhibited | ||
Amoebiasis | 0.005649 | 0.221723 | Inhibited | S | |
ovarian | Rap1 signaling pathway | 4.02E-05 | 0.002785 | Inhibited | N |
PI3K-Akt signaling pathway | 5.03E-05 | 0.002785 | Inhibited | N | |
Calcium signaling pathway | 5.32E-05 | 0.002785 | Inhibited | N | |
Focal adhesion | 0.000366 | 0.014354 | Inhibited | N | |
rectum | Focal adhesion | 3.63E-06 | 0.000342 | Inhibited | N |
Rap1 signaling pathway | 4.36E-06 | 0.000342 | Inhibited | N | |
Ras signaling pathway* | 1.32E-05 | 0.000689 | Inhibited | S | |
PI3K-Akt signaling pathway | 4.96E-05 | 0.001727 | Inhibited | N | |
Prostate cancer* | 5.50E-05 | 0.001727 | Inhibited | S | |
Melanoma | 0.001514 | 0.039609 | Inhibited | S | |
uterine | Focal adhesion | 7.50E-07 | 0.000118 | Inhibited | N |
Maturity onset diabetes of the young | 4.69E-05 | 0.003144 | Activated | S | |
Calcium signaling pathway | 6.01E-05 | 0.003144 | Inhibited | N | |
Rap1 signaling pathway | 0.005318 | 0.208728 | Inhibited | N |